McDermott Will & Schulte advised MaaT Pharma, a clinical-stage biotechnology company and leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving the survival of cancer patients through modulation of the immune system, in connection with a capital increase of approximately €9 million, comprising an offering of new ordinary shares to qualified investors and a public offering of new ordinary shares to retail investors (via the PrimaryBid platform).

Current shareholders Biocodex, the PSIM Fund represented by Bpifrance Investissement, and Invus Public Entities subscribed to the Global Offering for a total amount of €4.5 million, €1.5 million each. The total subscription amount of these investors represents approximately 49% of the Global Offering.

The McDermott Will & Schulte team on this transaction consisted of:

Emmanuelle Trombe and Bertrand Delafaye, partners; Sophie Lafay, counsel; and Henri Nalbandyan, associate.

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.